Podcasts about ignyte

In today's episode, supported by Replimune, we had the pleasure of speaking with Anna C. Pavlick, BSN, MSc, DO, MBA, about the use of RP1 plus nivolumab (Opdivo) for the treatment of patients with advanced melanoma. Dr Pavlick is a professor of medicine in the Division of Hematology & Medical Oncology at Weill Cornell Medicine in New York, New York; as well as the founding director of the Cutaneous Oncology Program at Weill Cornell Medicine and NewYork-Presbyterian. In our exclusive interview, Dr Pavlick discussed the rationale for investigating this combination in patients with advanced melanoma who have received prior immune checkpoint inhibition, key efficacy and safety findings from the phase 1/2 IGNYTE trial (NCT03767348), and where the future may be headed regarding the use of oncolytic viruses in melanoma.

Sometimes, people will say of a book that "the setting is another character". But what does that really mean, and how can a writer craft it? Ai Jiang joins us to discuss creating worlds and settings that have their own personalities! From the physical geography to the architecture, from the scale of the location to its dynamism, writers can make a lot of choices to make their setting feel unlike any other. The setting can do a lot to set the mood and tone of a story. Is it bright and peppy, or dark and gloomy? What's the vibe? The overlap between setting and aesthetic can be quite high, communicating a lot to your reader about what they might expect from the story and characters. We also often talk about how characters are the products of their circumstances -- and that means they're also products of their surroundings! What about the physical space that they exist in, or have existed in during their life, has shaped them? [Transcript TK] Our Guest: Ai Jiang is a Chinese-Canadian writer, Ignyte, Bram Stoker, and Nebula Award winner, and Hugo, Astounding, Locus, Aurora, and BFSA Award finalist from Changle, Fujian currently residing in Toronto, Ontario. Her work can be found in F&SF, The Dark, The Masters Review, among others. She is the recipient of Odyssey Workshop's 2022 Fresh Voices Scholarship and the author of A Palace Near the Wind, Linghun and I AM AI. Find her on X (@AiJiang_), Insta (@ai.jian.g), and online (http://aijiang.ca). 

Send us a textIn today's episode, Alex talks with Ai Jiang, the author of multiple award-winning short fiction and the highly anticipated A PALACE NEAR THE WIND (releasing April 15th). Ai is a Chinese-Canadian writer, Ignyte, Bram Stoker, and Nebula Award winner, and Hugo, Astounding, Locus, Aurora, and BFSA Award finalist from Changle, Fujian, currently residing in Toronto, Ontario. She is the recipient of Odyssey Workshop's 2022 Fresh Voices Scholarship and the author of A Palace Near the Wind, Linghun, and I AM AI.Listen as they discuss who Ai's literary heroes are, her experimental storytelling inspiration and why A PALACE NEAR THE WIND utilizes a more traditional story structure, how she challenges herself as a writer to avoid getting stuck in old habits, and how to stay true to art in a literary landscape that is favoring the use of AI and fast-fashion esque publishing models. Due to character limitations, please find a full version of the show notes with applicable content warnings and links on our website at: https://www.tarakross.com/podcast-1→  Connect with Ai on her Instagram or visit her website → Pre-order or Buy A PALACE NEAR THE WIND  HEREThe Hope Prose Podcast's InstagramAlex's Instagram Tara's Instagram

Listen to the Monetize Talks coverage. In this episode, Adam Torres interviews Diego Alba, Founder of Ignyte, explore Ignyte and the Monetize Talks event. Follow Adam on Instagram at https://www.instagram.com/askadamtorres/ for up to date information on book releases and tour schedule. Apply to be a guest on our podcast: https://missionmatters.lpages.co/podcastguest/ Visit our website: https://missionmatters.com/ More FREE content from Mission Matters here: https://linktr.ee/missionmattersmedia Learn more about your ad choices. Visit podcastchoices.com/adchoices

Host Jason Blitman talks to Rivers Solomon about their latest book, Model Home, discussing its unique spin on the haunted house genre and the layers of personal and family dynamics within. Guest Gay Reader Margaret Cho shares anecdotes from her eclectic career and childhood experiences growing up in a gay bookstore, all while reflecting on her love for reading. Rivers Solomon writes about life in the margins, where they are much at home. In addition to appearing on the Stonewall Honor List and winning a Firecracker Award, Solomon's debut novel, An Unkindness of Ghosts, was a finalist for Lambda, Hurston/Wright, Otherwise (formerly Tiptree), and Locus Awards. Solomon's second book, The Deep, based on the Hugo-nominated song by the Daveed Diggs–fronted hip-hop group clipping, was the winner of the 2020 Lambda Award and was short-listed for the Nebula, Locus, Hugo, Ignyte, Brooklyn Library Literary, British Fantasy, and World Fantasy Awards. Their work appears in Black Warrior Review, The New York Times, The New York Times Magazine, Guernica, Best American Short Stories, Tor.com, Best American Horror and Dark Fantasy, and elsewhere. A refugee of the transatlantic slave trade, Solomon was born on Turtle Island but currently resides on an isle in an archipelago off the western coast of the Eurasian continent.Margaret Cho Comedian. Actor. Musician. Advocate. Entrepreneur. Five-time Grammy and Emmy nominee.  Margaret Cho's strong voice has been lighting the path for other women, other members of underrepresented groups, other performers, to follow. Her recent television appearances – guest star on Season 2 of The Flight Attendant (HBO Max), guest star on Season 2 of Hacks (HBO Max) and two Netflix is a Joke comedy specials: Stand Out: An LGBTQ+ Celebration and Jane Fonda & Lily Tomlin: Ladies Night Live – have expanded an already wide-ranging career, and her role as the ‘mother hen' in the well-reviewed movie Fire Island solidifies why we all love Margaret in the first place. As a comedian Margaret has been named one of Rolling Stone magazine's 50 Best Stand-Up Comics of All Time, one of Vogue magazine's Top 9 Female Comedians of all time, while CNN chose her as one of the 50 People Who Changed American Comedy.  Thankfully, Margaret has more stories to tell, and her production company, Animal Family Productions, has multiple scripted shows in development for 2022 and beyond.BOOK CLUB!Use code GAYSREADING at checkout to get first book for only $4 + free shipping! Restrictions apply.http://aardvarkbookclub.comWATCH!https://youtube.com/@gaysreadingBOOKS!Check out the list of books discussed on each episode on our Bookshop page: https://bookshop.org/shop/gaysreading MERCH!Purchase your Gays Reading podcast merchandise HERE! https://gaysreading.myspreadshop.com/ FOLLOW!@gaysreading | @jasonblitman CONTACT!hello@gaysreading.com

Vajra Chandrasekera returns to Arcx for our season finale. Since we last spoke, Vajra has won a Nebula award, as well as Crawford and Locus awards for his debut novel, The Saint of Bright Doors. He has also been nominated for Le Guin, Ignyte, Hugo, Lammy, and British Fantasy Awards—and we're sure there are more in the pipeline!  Vajra's short stories, poems and articles have appeared in many publications over the years, including Clarkesworld and West Branch. He has also worked as an editor for Strange Horizons, and Afterlives: The Year's Best Death Stories.  In this episode, we delve into his second cross genre novel, Rakesfall, exploring the complexity of this fascinating novel that follows two characters across space, time, and life cycles and explores themes of power, resistance, and connections. We also discuss political oppression, genocidal playbooks, shifts in the publishing industry, South Asian writers, the flattened postcolonial world we live in, and much more.  You can follow Vajra Chandrasekera on X @_vajra   

I had a whole caption but overall I am cussing while discussingself preservation and the lack ofcommunityliterary workshop updatessupport Voodoonauts and vote for them for community in the Ignyte awardssupport one of the co-foundersfund, support, & sponsor Voodoonauts vote for me for CNF Lysz Flo - Magic in the RootsWish to work with me on a workshop?Contact me via my website or socials belowYou can continue the convo with me on⁣⁣

This week, speculative fiction writers Darcie Little Badger, Michi Trota, and Suzanne Walker discuss their work, crafting other worlds with writing, and the science fiction genre at large. This conversation originally took place May 19, 2024 and was recorded live at the American Writers Festival. AWM PODCAST NETWORK HOME About the writers: DARCIE LITTLE BADGER is a Lipan Apache writer with a PhD in oceanography. Her critically acclaimed debut novel, Elatsoe, was featured in TIME as one of the best 100 fantasy books of all time. Elatsoe also won the Locus Award for Best First Novel and was a Nebula, Ignyte, and Lodestar finalist. Her second fantasy novel, A Snake Falls to Earth, received the Newbery Honor, was a LA Times Book Prize Finalist, and was longlisted for the National Book Award. Darcie is married to a veterinarian named Taran and splits time between California and Texas. MICHI TROTA is a five-time Hugo Award-winning Filipino American writer, editor, and narrative expert. Her work explores how to use empowerment, representation, and storytelling to attain collective liberation and to dismantle oppressive institutions, not just survive them. She is the Executive Editor at the environmental justice and advocacy nonprofit Green America and her publications include the Wing Luke Museum 2018-19 exhibit Worlds Beyond Here: Expanding the Universe of APA Science Fiction and Chicago Magazine, and she's been featured in The Guardian, Chicago Tribune, and CNN: Philippines. She is also a member of the Filipino Young Leaders Program 2022 Immersion cohort and a fire performer with Raks Geek/Raks Inferno Fire+Bellydance. SUZANNE WALKER is a Chicago-based writer and editor. She is co-creator of the critically acclaimed, award-nominated graphic novel Mooncakes. Her short fiction has been published in Clarkesworld and Uncanny Magazine, and the Star Wars anthology From a Certain Point of View: Return of the Jedi. Her nonfiction works have appeared in a diverse array of publications, StarTrek.com, and academic anthologies. She has spoken on panels at numerous conventions on a variety of topics. She is a scholar of medieval Italian longsword and enjoys aerial silks, figure skating, and baseball. You can find her on Twitter or Instagram at @suzusaur.

Dr. Diwakar Davar and Dr. Jason Luke discuss advances in the neoadjuvant immunotherapy space that were presented at the 2024 ASCO Annual Meeting, including promising outcomes in high-risk melanoma from the NADINA trial, as well as other new treatment options for patients with advanced cancers.    TRANSCRIPT Dr. Diwakar Davar: Hello and welcome to the ASCO Daily News Podcast. I'm your guest host, Dr. Diwakar Davar, and I am an associate professor of medicine and the clinical director of the Melanoma Skin Cancer Program at the University of Pittsburgh's Hillman Cancer Center. I am delighted to have my colleague and friend Dr. Jason Luke on the podcast today to discuss key late-breaking abstracts and advances in immunotherapy that were presented at the 2024 ASCO Annual Meeting. Dr. Luke is an associate professor of medicine, the associate director of clinical research, and the director of the Cancer Immunotherapeutic Center at the University of Pittsburgh Hillman Cancer Center.   You will find our full disclosures in the transcript of this episode.  Jason, it's always a pleasure to hear your insights on the key trials in these spaces and to have you back as a guest on this podcast that highlights some of the work, especially advances, that were just presented. Dr. Jason Luke: Well, thanks very much for the invitation. I always love joining the podcast. Dr. Diwakar Davar: We'll start very quickly by talking about some advances and really interesting things that happened both in the context of melanoma but also in immunotherapy in general. And we'll start with what I think was certainly one highlight for me, which was LBA2, the late-breaking abstract on the NADINA trial. It was featured in the Plenary Session, and in this abstract, Dr. Christian Blank and colleagues reported on the results of this phase 3 trial of neoadjuvant ipi-nivo. This is the flipped dose of ipi1/nivo3 versus adjuvant nivolumab in PD-1 naive, macroscopic, resectable, high-risk stage 3 melanoma.  By way of background, neoadjuvant immunotherapy for those listening is an area of increasing interest for drug developers and development for both approved and novel agents. Neoadjuvant immunotherapy has been studied with multiple approved agents, including PD-1 monotherapy, PD-1 LAG-3, PD-1 CTLA-4, T-VEC, as well as investigational agents and multiple randomized and non-randomized studies. The benchmark pathologic response rates with these agents range from 17% PCR with PD-1 monotherapy, 45% to 55% PCR with PD-1 CTLA-4 combination therapy, and slightly higher 57% PCR with PD-1 LAG-3 has recently reported by Dr. Rodabe Amaria from MD Anderson. However, as we embark on phase 3 comparisons for various neoadjuvant compared to adjuvant immunotherapy trials and combinations, we're increasingly moving towards event-free survival as the primary endpoint for neoadjuvant versus adjuvant studies. And this was most recently studied in the context of SWOG S1801, a study that was led by Dr. Sapna Patel.  So, Jason, before we start on NADINA, can you briefly summarize the SWOG S1801 trial and the event-free survival statistic reported by Dr. Patel and her colleagues? Dr. Jason Luke: Well, absolutely. And these data were reported at ESMO about two years ago and then in the New England Journal last year. The S1801 study answered a very simple question: What would happen if you took three of the doses of standard adjuvant therapy with pembrolizumab and moved them prior to surgery? And on a high level, the study is as simple as that. And many of us were somewhat skeptical of this trial design because we thought that just moving the doses earlier may not actually have a major impact.  In the study, you alluded to the event-free survival statistic, and that alludes to what was considered an event. And so, without reading all of it, there were several different aspects that were included in terms of time, based on the date of randomization until the first of a series of events, such as disease progression, toxicity from treatment, if the patient was unable to go to surgery or had surgical complications, or if they had delay in starting the adjuvant therapy due to toxicity, and obviously, recurrence of melanoma or death from any cause. In that context, merely moving the 3 doses of pembrolizumab to the neoadjuvant setting saw an improvement in this two-year event free survival to 72% for the neoadjuvant therapy compared to 49% for the adjuvant therapy. That was quite an outstanding change. And again, noting the power of neoadjuvant treatment, really dictating the impact of anti PD-1, again, just with 3 doses moving from adjuvant into the neoadjuvant setting, and I think all of us were somewhat surprised to see that magnitude of a benefit. But it set up the current study very well, where we now look at combination therapy. Dr. Diwakar Davar: So let's move on to the phase 3 NADINA trial. Do you want to perhaps discuss the study design, particularly focusing on the EFS primary endpoint and maybe also touching on the different schedules? So, SWOG S1801 was a neoadjuvant study of 3 cycles of pembrolizumab and how did that compare and contrast to the neoadjuvant combination that was studied in NADINA? Dr. Jason Luke: Well, as you alluded to, NADINA investigated the regimen of nivolumab plus ipilimumab and compared that against adjuvant therapy with nivolumab alone. So, in the study, as you alluded, the dose and schedule of the two drugs used was nivolumab at 3 milligrams per kilogram, and ipilimumab with 1 milligram per kilogram. That was based on a series of signal finding and safety studies that had been previously done by the same group of authors identifying that as the optimal treatment regimen. And it's worth noting that's slightly different than the labeled indication that's generally used for those same drugs for metastatic melanoma, albeit that the NCCN also endorses this schedule. So, in the trial, 423 patients were randomized, 1:1 to receive either neoadjuvant therapy with those 2 doses of nivolumab plus ipilimumab as compared with standard adjuvant therapy with nivolumab following surgery.   Now, one interesting tweak was that there was an adaptive nature to the study, meaning that patients had a fiducial placed at the index lymph node, and after the neoadjuvant therapy in that arm, that lymph node was removed. And if the patient had a major pathological response, they did not go on to receive the adjuvant portion of the treatment. So it was adaptive because those patients who did very well to the neoadjuvant did not require the adjuvant portion. And in those patients who did not achieve a major pathological response, they could go on to have the adjuvant therapy. And that also included the BRAF therapy for those whose tumors were BRAF mutants.  It's also worth pointing out that the definition of event free survival was slightly different than in the S1801 study that was alluded to just a second ago. And here, EFS was defined from the date of randomization until progression due to melanoma or due to treatment. So that's slightly different than the definition in the S1801 trial. So, a somewhat complicated study, but I really applaud the authors because I think this study does mirror what we would likely be doing in actual clinical practice.  Dr. Diwakar Davar: So, just to briefly summarize the efficacy, and then to get your comments on this, the path response, the PCR rate was 47%. The major pathologic response rate, which is the proportion of patients with between 0% to 1/10% of residual viable tumors, was about 12%. And for a major pathologic response rate of 0% to 10% of 59%. And then the rest of the patients had either pathologic partial response, which was 10% to 50%, or pathologic non response or 50% or greater residual viable tumor, all assessed using central pathology grades. The one year RFS was 95% in the FDR patient population versus 76% in the pathologic partial response patient population, 57% in the pathologic non response patient population. So how do you view these results? Can you context the FDR rates and the EFS rates from NADINA relative to nivo-rela and also potentially SWOG 1801? Dr. Jason Luke: Well, I think these are very exciting results. I think that for those of us that have been following the field closely, they're actually not especially surprising because they mirror several studies that have come before them. When we put them in context with other studies, we see that these rates of major pathological response are consistent with what we've seen in phase 2 studies. They're relatively similar. Or I should say that the results from nivolumab and relatlimab, which was also pursued in a phase 2 study of somewhat similar design, are somewhat similar to this. So, combination immunotherapy does look to deliver a higher major pathological response than pembrolizumab alone, as was known in S1801. Which of course, the caveat being is these are cross control comparisons that we need to be careful about. So I think all of these are active regimens, and I think adding a second agent does appear to enhance the major pathologic response rates. When we look at the event free survival, we see something similar, which is that numerically it looks to be that combination immunotherapy delivers a higher event free survival rate. And that looks to be rather meaningful given the difference in the hazard ratios that were observed between these various studies. And here in the NADINA study, we see that 0.3 hazard ratio for EFS is just extremely impressive.  So the abstract then, from ourselves, out of these specific studies, what does this mean more broadly in the real world, where patients exist and the rest of the landscape for clinical trials? I think we can't take enough time to stop for a second and just think about what a revolution we've come forward in with immune checkpoint blockade and melanoma. When I started my career, now, more than 15 years ago, melanoma was the cancer that made cancer bad. And now here we say, in the highest risk of perioperative patients, we can deliver 2 doses of nivolumab and ipilimumab, and essentially half of the patients then don't need to go on, and more than half the patients don't need to go on to have a full surgery and don't need adjuvant therapy. And from what we could tell of a very, very low risk of every heavy recurrence of melanoma. Of course, there's the other half of patients where we still need to do better, but these are just fantastic results and I think highly meaningful for patients.   In the context of ongoing clinical trials, another abstract that was presented during the meeting was the update to the individualized neoantigen therapy, or V940 with pembrolizumab or against pembrolizumab alone. That's the KEYNOTE-942 study. In that study, they presented updated data at two and a half years for relapse free survival, noting a 75% rate without relapse. So those results are also highly intriguing. And these are in a similar population of very high risk patients. And so I think most of us believe that neoadjuvant therapy with this study in NADINA is now confirmed as the priority approach for patients who present with high-risk stage 3 disease. So that would be bulky disease picked up on a scan or palpable in a clinic. I think essentially all of us now believe patients should get preoperative immunotherapy. We can debate which approach to take, and it may vary by an individual patient's ability to tolerate toxicity, because, of course, multi agent immunotherapy does have increased toxicity relative to anti PD-1 alone. But we'll have to wait now for the full phase 3 results from the V940 individualized neoantigen therapy. And if those come forward, that will be an extremely attractive approach to think about for patients who did not achieve a major pathological response to neoadjuvant therapy, as well as of course to the other populations of patients with melanoma where we otherwise currently give adjuvant therapy stage 2B all the way through stage 4 resected. It's an amazing time to think about perioperative therapy in melanoma. Dr. Diwakar Davar: So this is clearly outstanding data, outstanding news. Congratulations to the investigators for really doing what is an investigative initiated trial conducted across multiple continents with a huge sample size. So this clearly appears to be, at this point in time at least, a de facto standard. But is this going to be FDA-approved, guideline-approved, or is it possible in your mind? Dr. Jason Luke: Well, that's an interesting question. This study was not designed with the intent to necessarily try to register this treatment regimen with the FDA. One would have to take a step back and say, with how powerful these data appear, it sort of seemed like it would be too bad if that doesn't happen. But all the same, I think the community and those of us who participate in guideline recommendations are fully supportive of this. So, I think we will see this move into compendium listings that support insurance approval, I think, very, very quickly. So, whether or not this actually becomes formally FDA approved or is in the guidelines, I think this should become the standard approach that is considered for patients, again presenting with high-risk stage 3 disease.  Dr. Diwakar Davar: Fantastic. So now we're going to go in and talk about a slightly different drug, but also from the melanoma context, and that is the safety and efficacy of RP1 with nivolumab in the context of patients with melanoma who are PD-1 failures. So, this is Abstract 9517. And in this abstract, our academic colleagues essentially talked about these data, and we'll start by describing what RP1 is. RP1 essentially is a HSV-1 based oncolytic immunotherapy. And RP1 expresses GM-CSF as well as a fusogenic protein, GALV-GP-R-. And in this abstract, Dr. Michael Wong from MD Anderson and colleagues are reporting the results of IGNYTE, which is a phase I trial of intratumoral RP1 co-administered with systemic nivolumab in patients with advanced metastatic treatment refractory cutaneous melanoma. And the data presented in this abstract represents data from a registration directed, abbreviated as RD, registration directed cohort of RP1 plus nivolumab in PD-1 refractory melanoma. So, let's start with the description of the cohort.  Dr. Jason Luke: Right. So, in this study, there were a total of 156 patients who were presented, and that included an initial safety and dose finding group of 16, as well as the RD cohort, as you noted, of 140 patients. And it's important to point out that this was a cohort that was selected for a very strict definition of progression on anti PD-1, or a combination immunotherapy as their immediately prior treatment. So, all of the patients in the cohort had exposure to anti PD-1, and 46% of them had anti PD-1 plus anti CTLA4, nivolumab and ipilimumab as their immediately prior therapy. This was also a group of relatively high-risk patients when one considers stage. So, within the stage 4 population, the entry here included 51% who had stage M1B, C, and D melanoma. And that is worth pointing out because this is an injectable therapy. So, trials like this in the past have tended to be biased towards earlier stage, unresectable or metastatic melanoma, meaning stage 3B, 3C, 3D and then stage 4m1a. Again, to emphasize the point here, these were pretreated patients who had a strict definition of anti PD-1 resistance, and over half of them, in fact, had high-risk visceral metastatic disease.  In that context, it's very interesting to observe that the overall response rate was described in the total population, as 31%, and that included 12% who achieved complete response. And so, again, to make sure it's clear, we're talking about a treatment where the oncolytic virus is injected into one or multiple sites of recurrent disease, and then the patients administer nivolumab as per standard. And so, I think these data are quite intriguing. Again, such a high- risk population and their maturity now, with a follow-up of over a year, I think, makes this look to be a very interesting treatment option.  Dr. Diwakar Davar: I guess on that topic of mature follow-up, it probably would be important for us to inform our audience that the top line data for the primary analysis was actually just released, I think, earlier today, and wherein the central confirmed objective response rate was 34% by modified RECIST and 33% by RECIST, clearly indicating that these responses, as you noted, very treatment refractory patient population, these responses were clearly very durable. So, you mentioned that there were responses seen in uninjected visceral lesions, responses seen in both PD-1 and PD-1 CTLA-4 refractory patients. Can you talk a little bit about the response rate in these high-risk subgroups, the uninjected visceral lesions, the patients who had both combination checkpoint and epidural refractory response rate by primary PD-1 resistance.  Dr. Jason Luke: Sure. You know, I think, again, to emphasize this point in the study, we saw that there were responses in the non-injected lesions, and I think it's really important to emphasize that. Some have referred to this as a putative abscopal like effect, similar to what is described in radiation. But it implies that local treatment with the oncolytic virus is triggering a systemic immune response. In the higher risk patient population, we'll note that whereas the overall response rate in PD-1 refractory patients was 34%, in the combination of PD-1 and CTLA-4 refractory patients, the response rate was 26%. So, [this is] still very good. And when we looked at that split by stage, as I alluded to before, in the population of patients that had, what you might call earlier unresectable diseases, so 3B through 4A, the response rate was 38%, and in the stage 4 M1b through M1d, it was 25%. So slightly lower, but still very good. And that would be as expected, because, of course, the patients with visceral metastatic disease have more advanced disease, but those response rates look quite good. Again, looking at the combination refractory population as well as the more high-risk disease. Dr. Diwakar Davar: So, clearly, these are very promising data and exciting times for multiple investigators in the field and the company, Replimune, as well. So, what are the next steps? I believe that a registration trial is planned, essentially, looking at this with the goal of trying to get this combination registered. Can you tell us a little bit about IGNYTE-3, the trial design, the control arm, and what you foresee this trial doing over the next couple of years?  Dr. Jason Luke: So, as this agent has been maturing, it's worth pointing out that the company that makes this molecule, called RP1, but I guess now we'll have to get used to this name vusolimogene oderparepvec as the actual scientific term, they have been having ongoing discussions with the FDA, and there is the potential that this agent could come forward on an accelerated path prior to the results being released from a phase 3 trial. That being said, the phase 3 confirmatory study, which is called the IGNYTE-3 study, is in the process of being launched now. And that's a study investigating this molecule in combination with nivolumab, as was alluded to earlier, and a randomized phase 3 design, where that combination is compared with a physician's choice, essentially a chemotherapy-based option.   In that study, it will be 400 patients with stage 3B through stage 4; patients will have progressed on anti PD-1, either as a combination or in sequence, and then come on the study to be randomized to either vusolimogene oderparepvec plus nivolumab versus that physician's choice. And the physician's choice includes chemotherapy agents, but also nivolumab plus relatlimab as another option, or an anti PD-1 monotherapy, if that's deemed to be a reasonable option by the treating investigator. And the primary endpoint of that study is overall survival. And unfortunately, in this highly refractory patient population, that's something that may not take long to identify with key secondary endpoints of progression free survival, as well as overall response rate. I'm quite enthusiastic about this study, given these data, which have now been centrally confirmed as you alluded to before. I think this is a very exciting area of investigation and really crossing my fingers that this may be perhaps the first locally administered therapy which does appear to have a systemic impact that can hold up in phase 3. Dr. Diwakar Davar: Very, very, very exciting results. And I guess it's worthwhile pointing out that this company also has got, I think, multiple studies planned with both RP1 and cutaneous squamous cell carcinoma in a solid organ transplant patient population where single agent activity has already been reported by Dr. Migden at prior meetings, as well as a novel trial of potentially RP2 metastatic uveal melanoma. So we'll now pivot to Abstract 6014. So, 6014 is a drug by a company known as Merus. Essentially, it's a very novel agent. Merus essentially is a company that is specialized in making bicyclics and tricyclics. And these are not bicycles or tricycles, but rather drugs that essentially are bispecific antibodies. And Merus essentially has come up with petosemtamab. I think we're going to have to figure out better names for all of these drugs at some point. But petosemtamab, or MCLA-158, essentially is a bicyclic, targeting both EGFR as well as LGR-5. So EGR-5, of course, is a known oncogenic driver in multiple tumor types, squamous, including non small cell lung cancer, cutaneous squamous cell carcinoma, but also head and neck squamous cell carcinoma. And LGR-5 essentially is leucine-rich repeat-containing G-protein coupled receptor 5, but it's a receptor in cancer stem cells and certainly highly expressed in head neck squam. And MCLA-158, or petosemtamab is a IgG one bispecific with ADCC-activity because of IgG1 backbone co-targeting EGFR and LGR5. Merus had earlier results that evaluated petosemtamab monotherapy. They defined the RP2D and second- and third-line head and neck blastoma patients with a respectable response rate of 37% investigator-assessed ORR with six months median DoR, and this was published by Ezra Cohen about a year or so ago.  In this abstract, Dr. Fayette and colleagues report on the results of the MCLA-158-CL01 trial, which is a trial of pembrolizumab plus petosemtamab in one front line head and neck squamous cell population. So maybe let's start with the description of the cohort. And it is a small trial, but we'll be able, I think, to dig into a little bit about why this might be exciting. Dr. Jason Luke: Yes. So, as alluded to, it's not the biggest trial as yet, but there were 26 patients with anti PD-1 treatment naive head and neck squamous cell carcinoma. And all the patients in the study did receive, as you alluded to, pembrolizumab plus petosemtamab. Based on the label for pembrolizumab, all the patients in this study were PDL-1 positive. So that's one point that it's worth pointing out to make sure that that's understood. This is the population of patients who would be expected to benefit from pembrolizumab in the first place. Now, in the abstract, they reported out only 10 response evaluable patients, but they updated that in the actual slides of presentation at the meeting. So among 24 patients that were alluded to, 67% were described as having had a response, although some of those were yet to be confirmed responses. And when it was evaluated by PDL-1 status, there didn't seem to be a clear enrichment of response in the PD-1 positive more than 20% group, as compared to the 1-19% group. That isn't especially surprising because that was a trend that one would see, presumably with pembrolizumab alone. But overall, I think these data are pretty exciting in terms of a preliminary study. Dr. Diwakar Davar: You know, you mentioned that the objective response rate was high, almost 60-something%. The prognosis of these patients is generally poor. The OS is typically thought of as between 6-15 months. And based on KEYNOTE-048, which was led by Dr. Burtness and colleagues, the standard of care in the setting is pembrolizumab +/- platinum based chemotherapy regimens. Allowing for the fact that we only have 10 patients here, how do you think these results stack up against KEYNOTE-048? And you made a very important point earlier, which was, by definition, pembro is on label only for the CPS. So PDL-1 score, at least in head and neck squamous cell carcinoma CPS and not TPS. But in the CPS 1% or greater patient population, where pembro is on label, how do these results stack up against the KEYNOTE-048 results. Dr. Jason Luke: Right. KEYNOTE-048 is considered the seminal study that dictates frontline treatment in head and neck cancer. And before we dive into this too far, we do want to acknowledge that here we're comparing 26 patients versus a phase 3 trial. So, we're not trying to get too far ahead of ourselves, but this is just a preliminary comparison. But in KEYNOTE-048, as you alluded to, two regimens were superior to chemotherapy. One was the pembrolizumab monotherapy, as well as pembrolizumab plus chemotherapy. So again, the study overall survival, of course, was much higher, the PDL-1 positive subgroup, which is what dictated the unlabeled use of this. But response to pembro monotherapy in that population of patients is still modest. We're talking about upwards of 20-30%. So, if you compare that to, again, preliminary evidence here from this trial of only 24 patients, that response rate of 60% seems extremely high. And so even if that were to come down somewhat in a larger data series of patients, that still looks to be quite promising as a treatment regimen, that might eventually even be chemotherapy sparing for this population of patients. I think this raises a lot of eyebrows that perhaps this dual targeting approach, EGFR and LDR-5, may bring something really important to the field that evolves it. Dr. Diwakar Davar: So, what are the next steps for petosemtamab? You mentioned that the activity was interesting. Are we going to see a larger trial? Any thoughts on where things are going to go?  Dr. Jason Luke: Well, based on the phase 2 data of petosemtamab alone, even without pembrolizumab, the molecule had already been given fast track designation by FDA, which means allowing for greater communication between the drug sponsor in the FDA and designing a seminal study design. One would assume that this trial will be rapidly expanded quite greatly, perhaps to 100 or 200 patients, to try to flush out what the real response rate is in a more meaningful number of patients. But I think these data will probably also trigger the design and probably near-term evaluation or expedited acceleration of a phase III clinical trial design that would potentially validate this against the current standard of care. So, I'm pretty excited. I think we'll see a lot more about this agent in the relatively near future. Dr. Diwakar Davar: So, finally, we'll pivot to the last abstract that we're going to talk about, which is Abstract 2504. It's a relatively interesting target, CCR8 monoclonal antibody. But this is the efficacy and safety of LM-108, and LM-108 is an anti CCR8 monoclonal antibody that is being developed by LaNova Medicine. And the results that are described, actually a pool set of results of combinations of LM-108 with anti PD-1, two separate anti PD-1, in patients with gastric cancer, mostly done ex-U.S., which is interesting because of this patient population, and it's a pool result of several, 3 phase 1 and 2 studies.  LM-108 is an Fc-optimized anti CCR8 monoclonal antibody that selectively depletes tumor infiltrating Tregs. The abstract reported a pooled analysis of three phase 1, 2 trials with 3 different NCT numbers that all evaluated the efficacy of LM-108 and anti PD-1 in patients with gastric cancer. So, let's start with the description of the cohort. Maybe, Jason, you can tell us a little bit about before you start, as you describe the cohort, sort of what we know, editorially speaking, about the difficulty with which Tregs depletion has been tried and obviously failed up until now in the tumor microenvironment. Dr. Jason Luke: Right. I think that's a really interesting comment. And so, for decades, in fact, targeting regulatory T-cell to alleviate immune exclusion in the tumor microenvironment has been of interest in immuno-oncology. And in preclinical mouse models, it seems quite clear that such an approach can deliver therapeutic efficacy. However, by contrast, in human clinical trials, various different Treg depleting strategies have been attempted, and there's really little to no evidence that depleting Tregs from human tumors actually can deliver therapeutic responses. And by that we're referring to CD-25 antibodies. The drug ipilimumab, the CTLA-4 antibody, was punitively described as a Tregs depleter preclinically, but that doesn't seem to be the case in patients. And so, in that background, this is quite an eye raiser that an anti CCR8 antibody could be driving this effect. Now, before we talk about the results of this trial, I will point out, however, that given the Fc-optimization, it's entirely possible that the Tregs are being depleted by this mechanism, but that more could also be going on. Because Fc gamma RII binding by this antibody that could be nonspecific also has the potential to trigger immune responses in the tumor microenvironment, probably mediated by myeloid cells. So I think more to come on this. If this turns out to be the first meaningful Tregs depletor that leads to therapeutic efficacy, that would be very interesting. But it's also possible this drug could have multiple mechanisms.  So, having said all of that, in the clinical trial, which was a pooled analysis, like you mentioned, of LM-108 in combination with anti PD-1 of a couple different flavors, there were 48 patients treated either with LM-108, with pembrolizumab, or with toripalimab, which is another anti PD-1 antibody. On the drug combination was, generally speaking, pretty well tolerated, noting grade 3 treatment related adverse events in the range of 38%, which is somewhat expected given combination immunotherapy. We talked about nivolumab and ipilimumab before, which, of course, gives even higher rates of immune-related adverse events, with the most common toxicities being anemia, lipase elevations, rash, ALC decrease; albeit, quite manageable. Dr. Diwakar Davar: So, what about the objective response rate? Can you contextualize the efficacy? And as you do that, maybe we'll think about what you'd expect in the context of, say, gastric cancer, especially in patients who've never really had a prior checkpoint inhibitor before. What do you think about the ORR? What do you think about the relative efficacy of this combination? Dr. Jason Luke: Well, so, in the study, they described overall response rate in the 36 patients as 36% and described immediate progression for survival of about 6.5 months. And so that was among patients who were treatment naive. And in second-line patients, they actually described an even higher response rate, although it was only 11 patients, but they're at 64%. And so, I think those data look to be somewhat interesting. When I was actually scrutinizing the actual data presented, it was of some interest to note that the quality of responses seemed to be about as good on the lower dose of LM-108, so 3 milligrams per kilogram as compared to 10 milligrams per kilogram. I think there's definitely more to learn here to try to optimize the dose and to fully understand what the overall efficacy of this treatment combination would be.  I would emphasize that in this disease, I think novel treatment strategies are certainly warranted. While anti PD-1 with chemotherapy has moved the needle in terms of standard of care treatment, it's really only a minor subset of patients who derive durable long-term benefit like we normally associate with immune checkpoint blockade. I think these are preliminary data. They're very intriguing.   You alluded to earlier that this population of patients was an Asian data set, and it is well known that the efficacy of chemotherapy and immunotherapy does appear to be somewhat enhanced in Asian populations, and that goes to distributions of metastasis and tumor microenvironment effects, etc. Very difficult to try to tease any of that out in this abstract, other than to look at these data and suggest that this is pretty interesting, both from a novel therapeutic approach, we talked about the Tregs consideration, but also straight up on the efficacy because I think if these data could hold up in a larger number of patients, and particularly in a western population of patients, I think it would be very intriguing. Dr. Diwakar Davar: Certainly, ASCO 2024 had a lot of interesting data, including data from targeted agents, the LAURA trial, ADCs. But just focusing on the immune therapy subset, we certainly saw a lot of great advances in patients who were treated with neoadjuvant as well as relapse refractory disease in the context of RP1 and then a couple of newer agents such as this petosemtamab as well as LM-108. And of course, we cannot forget to highlight the extended DMFS data from the pembro vaccine study from KEYNOTE-942.  Jason, as always, thank you for taking a little bit of time out of your extremely busy schedule to come and give us insights as to how these agents are impacting the landscape. We really value your input and so thank you very much.  Dr. Jason Luke: Thank you for the opportunity. Dr. Diwakar Davar: And thank you to our listeners for your time today. You will find the links to all the abstracts that we discussed in the transcript of this episode. And finally, if you value the insights that you hear on this podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. So, thank you.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Follow today's speakers:   Dr. Diwakar Davar   @diwakardavar   Dr. Jason Luke   @jasonlukemd      Follow ASCO on social media:    @ASCO on Twitter   ASCO on Facebook   ASCO on LinkedIn      Disclosures:       Dr. Diwakar Davar:     Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences    Consulting or Advisory Role: Instil Bio, Vedanta Biosciences    Consulting or Advisory Role (Immediate family member): Shionogi    Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences    Research Funding (Inst.): Zucero Therapeutics    Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy       Dr. Jason Luke:    Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX    Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine    Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure    Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)    Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

Podcast: (CS)²AI Podcast Show: Control System Cyber SecurityEpisode: 111: From Scrubbing Hard Drives to Securing the Future: Max's Journey in CybersecurityPub date: 2024-05-28We are thrilled to have Max Aulakh, the Founder and CEO of Ignyte Assurance Platform, joining us today. Max is a military veteran and motorcycle enthusiast who enjoys doing voluntary work. He is a prolific contributor to the cybersecurity community, always willing to be of service to others. When Max was three, his father applied for American citizenship at the US Embassy in India. It was an extremely long process, and after losing all hope, he and his family finally migrated to Oklahoma a decade later. Join us to learn how Max transitioned from the military to founding the successful Ignyte Assurance Platform. He also shares his views on regulations, discusses how AI has impacted the security field, and offers prudent and practical advice for anyone interested in pursuing a cybersecurity career. Stay tuned for today's candid and fascinating interview with Max Aulakh, the Founder and CEO of Ignyte.Show highlights:How Max's military experience led to his career in securityMax's Air Force mentor encouraged voluntary service.How working with the Department of Treasury, scrubbing hard drives, led to Max's interest in security.Max explains how his military experience instilled a service mindset beneficial for security roles.While in service, he attended the American Military University due to its flexible programs for deployed personnel.The challenges he faced transitioning from a services company to a product-based companyMax shares how he launched Ignyte in 2019/2020How Max assists companies with the Cybersecurity Maturity Model, particularly in thedefense sector.Why standardization and testing are essential in operational technologyMax shares his views on the potential of AILinks and resources:(CS)²AI Derek Harp on LinkedInIgnyte Assurance PlatformMax Aulakh on LinkedInThe podcast and artwork embedded on this page are from Derek Harp, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.

Podcast: (CS)²AI Podcast Show: Control System Cyber SecurityEpisode: 111: From Scrubbing Hard Drives to Securing the Future: Max's Journey in CybersecurityPub date: 2024-05-28We are thrilled to have Max Aulakh, the Founder and CEO of Ignyte Assurance Platform, joining us today. Max is a military veteran and motorcycle enthusiast who enjoys doing voluntary work. He is a prolific contributor to the cybersecurity community, always willing to be of service to others. When Max was three, his father applied for American citizenship at the US Embassy in India. It was an extremely long process, and after losing all hope, he and his family finally migrated to Oklahoma a decade later. Join us to learn how Max transitioned from the military to founding the successful Ignyte Assurance Platform. He also shares his views on regulations, discusses how AI has impacted the security field, and offers prudent and practical advice for anyone interested in pursuing a cybersecurity career. Stay tuned for today's candid and fascinating interview with Max Aulakh, the Founder and CEO of Ignyte.Show highlights:How Max's military experience led to his career in securityMax's Air Force mentor encouraged voluntary service.How working with the Department of Treasury, scrubbing hard drives, led to Max's interest in security.Max explains how his military experience instilled a service mindset beneficial for security roles.While in service, he attended the American Military University due to its flexible programs for deployed personnel.The challenges he faced transitioning from a services company to a product-based companyMax shares how he launched Ignyte in 2019/2020How Max assists companies with the Cybersecurity Maturity Model, particularly in thedefense sector.Why standardization and testing are essential in operational technologyMax shares his views on the potential of AILinks and resources:(CS)²AI Derek Harp on LinkedInIgnyte Assurance PlatformMax Aulakh on LinkedInThe podcast and artwork embedded on this page are from Derek Harp, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.

We are thrilled to have Max Aulakh, the Founder and CEO of Ignyte Assurance Platform, joining us today. Max is a military veteran and motorcycle enthusiast who enjoys doing voluntary work. He is a prolific contributor to the cybersecurity community, always willing to be of service to others. When Max was three, his father applied for American citizenship at the US Embassy in India. It was an extremely long process, and after losing all hope, he and his family finally migrated to Oklahoma a decade later. Join us to learn how Max transitioned from the military to founding the successful Ignyte Assurance Platform. He also shares his views on regulations, discusses how AI has impacted the security field, and offers prudent and practical advice for anyone interested in pursuing a cybersecurity career. Stay tuned for today's candid and fascinating interview with Max Aulakh, the Founder and CEO of Ignyte.Show highlights:How Max's military experience led to his career in securityMax's Air Force mentor encouraged voluntary service.How working with the Department of Treasury, scrubbing hard drives, led to Max's interest in security.Max explains how his military experience instilled a service mindset beneficial for security roles.While in service, he attended the American Military University due to its flexible programs for deployed personnel.The challenges he faced transitioning from a services company to a product-based companyMax shares how he launched Ignyte in 2019/2020How Max assists companies with the Cybersecurity Maturity Model, particularly in thedefense sector.Why standardization and testing are essential in operational technologyMax shares his views on the potential of AILinks and resources:(CS)²AI Derek Harp on LinkedInIgnyte Assurance PlatformMax Aulakh on LinkedIn

Gary and Jonathan are joined by Tobi Ogundiran, whose novella In the Shadow of the Fall is the first of the “Guardian of the Gods,” and whose first story collection Jackal, Jackal, was published to considerable acclaim last year. Winner of the Ignyte and nominee for the BSFA, and Shirley Jackson awards, Tobi discusses growing up in Nigeria reading what SFF he could come across, the importance of discovering FIYAH as a place for his fiction, the relationship between Western and African storytelling traditions, managing viewpoints and voices, and his own plans for the future. As always, our thanks to Tobi for making time to talk to us. We hope you enjoy the podcast!

In this episode of the Libro.fm Podcast Extravaganza, Craig and Karen interview Dr. Darcie Little Badger, author of "Elatsoe" and the prequel "Sheine Lende." Dr. Little Badger discusses her background as an oceanographer and her transition to full-time writing, the influence of her family on her work, and indigenous futurism. Photo: Bekah M. Photography READ TRANSCRIPT Use promo code: SWITCH when signing up for a new Libro.fm membership to get 2 extra free credits to use on any audiobooks. About Dr. Darcie Little Badger: Darcie Little Badger is a Lipan Apache writer with a PhD in oceanography. Her critically acclaimed debut novel, Elatsoe, was featured in Time Magazine as one of the best 100 fantasy books of all time. Elatsoe also won the Locus award for Best First Novel and is a Nebula, Ignyte, and Lodestar finalist. Her second fantasy novel, A Snake Falls to Earth, received a Nebula Award, an Ignyte Award, and a Newbery Honor and is on the National Book Awards longlist. Her third book, Sheine Lende, is the prequel to Elatsoe and will be published in 2024. Read Darcie's books: Elatsoe Sheine Lende A Snake Falls to Earth Books discussed on today's episode: Sing, Unburied, Sing by Jesmyn Ward The Grip of It by Jac Jemc James by Percival Everett

Critters, creatures, and things that crawl -- part of the fun of building a new world is getting to populate it with not just sapient characters, but all the flora and fauna. And sometimes, that means the things you find in the smallest corners and crevices. Guest Premee Mohamed joins us to talk about the role of bugs and other biology in worldbuilding! Bugs are a critical part of our world, performing so many essential functions that we never think about and that writers often neglect -- so, why is that? Where does our tendency towards squeamishness about bugs overlap with fears of body horror -- and how have SFF stories magnified those fears to create memorable antagonists like Xenomorphs and monsters like Shelob? How can a worldbuilder think about the health of their whole ecosystem, from those itsy-bitsy bugs all the way up to the apex predators -- and if the health of the ecosystem reflects the health of the world, how can that provide some good plot hooks for characters? All this and many, many scientific factoids are packed into this episode! [Transcript TK] Our Guest: Premee Mohamed is a Nebula, World Fantasy, and Aurora award-winning Indo-Caribbean scientist and speculative fiction author based in Edmonton, Alberta. She has also been a finalist for the Hugo, Ignyte, Locus, British Fantasy, and Crawford awards. Currently, she is the Edmonton Public Library writer-in-residence and an Assistant Editor at the short fiction audio venue Escape Pod. She is the author of the 'Beneath the Rising' series of novels as well as several novellas. Her short fiction has appeared in many venues and she can be found on her website at www.premeemohamed.com. 

Broken to the Fist. Friend of the pod and Creator of Counterpart, Justin Marks, is back on tv with Rachel Kondo for Hulu's Shōgun. Red & Ivan are joined by Award winning Author and friend of the pod, Maggie Tokuda-Hall!!! Pre-Order Maggie's Graphic Novel, The Worst Ronin!!!! Maggie is the author of the 2017 Parent's Choice Gold Medal winning picture book, Also an Octopus, illustrated by Benji Davies. The Mermaid, the Witch, and the Sea is her debut young adult novel, which was an NPR, Kirkus, School Library Journal and Book Page Best Book of 2020. Its sequel, The Siren, The Song and The Spy comes out September 2023. Her graphic novel, Squad, is an Ignyte and Locus Award nominated comic book, and her newest picture book, Love in the Library, has been named a Best Picture Book of 2022 by Book Page, School Library Journal, Booklist, and Publisher's Weekly. Maggie is a founding member of Authors Against Book Bans. She lives in Oakland, California with her husband, children, and objectively perfect dog.  Also, check out Red & Maggie Tokuda-Hall's podcast, Failure to Adapt, available on Spotify, Apple Podcasts, or via RSS As always: Support Ivan & Red! → patreon.com/boarsgoreswords Follow us on twitter → @boarsgoreswords Find us on facebook → facebook.com/BoarsGoreSwords

Welcome back to the UNTOLD LEGENDS podcast hosted by Natalie C. Parker & Zoraida Córdova. We've had a little bit of a rebrand, so if you remember VAMPIRES NEVER GET OLD, we are still the same editors and writers, we've just expanded. Join our dynamic duo as they're joined this time by the wonderful Darcie Little Badger. Together they discuss some fun (and deadly) marine facts along with what inspired her story in the anthology from the perspective of a horror and fantasy lover. Darcie Little Badger is a Lipan Apache writer with a Ph.D. in oceanography. Her critically acclaimed debut novel, Elatsoe, was featured in Time Magazine as one of the best 100 fantasy books of all time. Elatsoe also won the Locus award for Best First Novel and is a Nebula, Ignyte, and Lodestar finalist. Her second fantasy novel, A Snake Falls to Earth, received a Nebula Award, an Ignyte Award, and a Newbery Honor and is on the National Book Awards longlist. Darcie is married to a veterinarian named Taran. She can be found on Instagram @dr.littlebadger. We also found Darcie's magical octopus! The Octopus Squid has bioluminescent arms and can drop one as a distraction as it escapes predators. Check out the Monterey Bay Aquarium website for more on this critter. Additional media mentioned: Creature from the Black Lagoon (1954), The Lighthouse (2019), Dagon (2001), The Shape of Water (2017), and Love, Death + Robots "Jibaro" (2022). Follow Zoraida Córdova @zoraidasolo and Natalie C. Parker @ncparker on Instagram.

NIGHTLIGHT is a World Fantasy and IGNYTE-award winning horror fiction podcast featuring creepy tales written by Black authors from all over the world. Episode 507: Loneliness is in Your Blood Show Notes / Transcript https://nightlightpod.com/ Learn more about your ad choices. Visit megaphone.fm/adchoices

Our esteemed guest, Sheree Renée Thomas, was kind enough to visit us and drop some knowledge. More info on her below! Sheree is a New York Times bestselling, two-time World Fantasy Award-winning author and editor. A 2023 Octavia E. Butler Award honoree and a 2022 Hugo Award Finalist, she is the author of Nine Bar Blues: Stories from an Ancient Future, a Locus, Ignyte, and World Fantasy Finalist, Marvel's Black Panther: Panther's Rage novel, and she collaborated with Janelle Monáe on “Timebox Altar(ed)” in The Memory Librarian and Other Stories of Dirty Computer. Sheree co-edited Africa Risen: A New Era of Speculative Fiction and is an NAACP Image Award Nominee and Editor of The Magazine of Fantasy & Science Fiction. Sheree lives in her hometown, Memphis, Tennessee, near a mighty river and a pyramid. Support F&SF: https://fandsf.com/ Find Sheree ONLINE: https://www.instagram.com/shereereneethomas/ https://www.shereereneethomas.com/ https://twitter.com/blackpotmojo  Leslye Penelope's podcast 'My Imaginary Friends': https://lpenelope.com/podcast/ --- Send in a voice message: https://podcasters.spotify.com/pod/show/afronauts-podcast/message

Arcx is all about literary inspiration. In the fifth episode of this season, host Anjali Alappat speaks with Saad Z. Hossain, the author of the best-selling Djinn series, which includes Djinn City, The Gurkha and the Lord of Tuesday, Kundo Wakes Up and Cyber Mage.  Saad's debut novel, Escape from Baghdad! was a finalist at the Grand Prix de L'imaginaire in 2018. The Gurkha and the Lord of Tuesday also received critical acclaim and was a finalist at the Locus Awards and the IGNYTE awards in 2020. Kundo Wakes Up, the sequel to The Gurkha and the Lord of Tuesday, was published in 2022, and made it to the Locus list of Best Novellas for 2022. It was also longlisted for the British Science Fiction Association Awards that year.  In this episode, we discuss classic literature, writing for fun, the importance of a snarky protagonist, Jane Eyre vs. Jane Austen, A.I in developing countries, philosophy, broken people, and of course, djinn. You can follow Saad on Twitter @saadzhossain Authors, books and media referenced in this episode: The Far Pavilions by M. M. Kaye  Pride and Prejudice by Jane Austen Mansfield Park by Jane Austen Persuasion by Jane Austen Sense and Sensibility by Jane Austen The Count of Monte Cristo by Alexandre Dumas  Arcx is a series of the Subverse, the podcast of Dark ‘n' Light, a digital space that chronicles the times we live in and reimagining futures with a focus on science, nature, social justice and culture. Follow us on social media @darknlightzine, or at darknlight.com for episode details and show notes.

Drs Sapna P. Patel and Kim A. Margolin sift through the data from studies presented at recent conferences, including the KEYNOTE-942 and RP1 IGNYTE studies. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/989036). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) https://classic.clinicaltrials.gov/ct2/show/NCT03897881?term=Keynote-942&draw=2&rank=1 A Personalized Cancer Vaccine, mRNA-4157, Combined With Pembrolizumab Versus Pembrolizumab in Patients With Resected High-Risk Melanoma: Efficacy and Safety Results From the Randomized, Open-Label Phase 2 mRNA-4157-P201/Keynote-942 Trial https://www.abstractsonline.com/pp8/#!/10828/presentation/10243 Distant Metastasis-Free Survival Results From the Randomized, Phase 2 mRNA-4157-P201/KEYNOTE-942 Trial https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.17_suppl.LBA9503 Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma https://pubmed.ncbi.nlm.nih.gov/36856617/ Pembrolizumab Versus Placebo as Adjuvant Therapy in Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase 3 KEYNOTE-716 Study https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.17_suppl.LBA9505 Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) https://www.clinicaltrials.gov/study/NCT03767348?term=Study%20of%20RP1%20Monotherapy%20and%20RP1%20in%20Combination%20With%20Nivolumab%20(IGNYTE)&rank=1 Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma https://pubmed.ncbi.nlm.nih.gov/33803762/ Randomized, Double-blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma https://pubmed.ncbi.nlm.nih.gov/35998300/ Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma https://oncologypro.esmo.org/meeting-resources/esmo-congress/phase-i-study-of-fianlimab-a-human-lymphocyte-activation-gene-3-lag-3-monoclonal-antibody-in-combination-with-cemiplimab-in-advanced-melanoma Significant Durable Response With Fianlimab (Anti-LAG-3) and Cemiplimab (Anti-PD-1) in Advanced Melanoma: Post Adjuvant PD-1 Analysis https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.9501?af=R Relatlimab and Nivolumab Versus Nivolumab in Untreated Advanced Melanoma https://pubmed.ncbi.nlm.nih.gov/34986285/ BRAF and MEK Inhibition in Melanoma https://pubmed.ncbi.nlm.nih.gov/25648338/ Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations https://pubmed.ncbi.nlm.nih.gov/29644214/ Society for Immunotherapy of Cancer (SITC) Consensus Definitions for Resistance to Combinations of Immune Checkpoint Inhibitors https://pubmed.ncbi.nlm.nih.gov/36918224/ RECIST 1.1 – Update and Clarification: From the RECIST Committee https://pubmed.ncbi.nlm.nih.gov/27189322/ Histopathological Features of Complete Pathological Response Predict Recurrence-Free Survival Following Neoadjuvant Targeted Therapy for Metastatic Melanoma https://pubmed.ncbi.nlm.nih.gov/32739408/

  Could the power of story-telling help create a better reality?  Afterglow is a stunning collection of original short stories in which writers from many different backgrounds envision a radically different climate future. Published in collaboration with Grist, a nonprofit media organization dedicated to telling stories of climate solutions, these stirring tales expand our ability to imagine a better world. Afterglow draws inspiration from a range of cutting-edge literary movements including Afrofuturism, hope-punk, and solar-punk—genres that uplift equitable climate solutions and continued service to one's community, even in the face of despair. The Indigenous, Latinx, Asian, disabled, feminist, and queer voices in this collection imagine intersectional worlds in which no community is left behind. Whether through abundance or adaptation, reform, or a new understanding of survival, these stories offer flickers of hope, even joy, as they provide a springboard for exploring how fiction can help create a better reality. Panelists Sheree Renée Thomas is a New York Times bestselling, two-time World Fantasy Award-winning author and editor. A 2023 Octavia E. Butler Award honoree and a 2022 Hugo Award Finalist, she is the author of Nine Bar Blues: Stories from an Ancient Future, a Locus, Ignyte, and World Fantasy Finalist, Marvel's Black Panther: Panther's Rage novel, and she collaborated with Janelle Monáe on “Timebox Altar(ed)” in The Memory Librarian and Other Stories of Dirty Computer. She co-edited Africa Risen: A New Era of Speculative Fiction, a NAACP Image Award Nominee, and is the Editor of The Magazine of Fantasy & Science Fiction. Sheree lives in her hometown, Memphis, Tennessee, near a mighty river and a pyramid. Justine Norton-Kertson is a genderfluid author of stories and poems as well as a screenwriter, game maker, musician, and community organizer. They're the founder and Editor-in-Chief of Android Press and Solarpunk Magazine. They've been published in magazines such as Utopia Science Fiction and Jupiter Review. Their anthologist debut, Bioluminescent: A Lunarpunk Anthology, was published in January 2023 from Android Press. And their debut nonfiction book, Solarpunk Witchcraft, is forthcoming from Microcosm Publishing in 2024. They live in rural Oregon with their partner, puppies, cats, goats, bunnies, and beehives. Find them at http://justinenortonkertson.com Andrew Simon is a writer and editor living in Seattle. Simon has been an editorial leader at award-winning media organizations including Grist, Fast Company, ESPN, and Complex Media. He's launched a journalism fellowship, the annual Grist 50 list, and a podcast, among other projects. He currently works on thought leadership and business solutions. He is co-author of the book ‘Racing While Black: How an African-American Stock Car Team Made Its Mark on NASCAR.' Tory Stephens creates opportunities that transform organizations and shift culture. He is a resource generator and community builder for social justice issues, people, and movements. He currently works at Grist Magazine as their climate fiction creative manager and uses storytelling to champion climate justice, and imagine green, clean, and just futures. In another life, he owned a kick-butt streetwear company, and he would have gotten away with eating the last cookie too if it weren't for his three meddling kids. Grist is a nonprofit, independent media organization dedicated to telling stories of climate solutions and a just future. Its goal is to use the power of storytelling to illuminate the way toward a better world, inspire millions of people to walk that path with us, and show that the time for action is now. Afterglow Third Place Books

In worldbuilding, we think a lot about the cities and towns that populate our worlds, as well as the enchanted forests, the treacherous mountain ranges, the gloomy swamps, and all those other terrains that adventurers on a quest find themselves trekking across. But what about the feature that makes up over 70% of our own planet and likely a significant percentage of the one you're creating? Darcie Little Badger joins us to talk about worldbuilding on and under the water! From the teeming biodiversity of coral reefs to the fascinatingly weird creatures of the depths, what inspiration can writers take from the oceans and seas? How do the denizens of your world flourish with -- or in spite of -- the effects the oceans have on them?   (Transcript tk) Our Guest: Darcie Little Badger is a Lipan Apache writer with a PhD in oceanography. Her critically acclaimed debut novel, Elatsoe, was featured in Time Magazine as one of the best 100 fantasy books of all time. Elatsoe also won the Locus award for Best First Novel and is a Nebula, Ignyte, and Lodestar finalist. Her second fantasy novel, A Snake Falls to Earth, received a Nebula Award, an Ignyte Award, and a Newbery Honor and is on the National Book Awards longlist. Darcie is married to a veterinarian named Taran.

Main Fiction: "The Moon and Mahasti" by Peter Adrian BehraveshPeter Adrian Behravesh is an Iranian-American musician, writer, editor, audio producer, and narrator. For these endeavors, he has won the Miller and British Fantasy Awards, and has been nominated for the Hugo, Ignyte, Stabby, and Aurora Awards. His interactive novel Heavens' Revolution: A Lion Among the Cypress, is forthcoming from Choice of Games, and his essay “Pearls from a Dark Cloud: Monsters in Persian Myth,” is forthcoming in The Oxford University Press Handbook of Monsters in Classical Myth. When he isn't crafting, crooning, or consuming stories, Peter can usually be found hurtling down a mountain, sipping English Breakfast, and sharpening his Farsi.This story originally appeared, in slightly different form, in Holy C.O.W: SF Stories from the Center of the World (Holy C.O.W Publishing, 2019).Narrated by: Tahereh Safavi Tahereh Safavi is grateful to be part of the Iranian diaspora, and for the opportunity that affords her to share art with the world. When she's not teaching wine-tasting, bellydance, or flying trapeze, she writes about medieval history with brown people–more at twodrunkhistorynerds.com. She's thrilled to help get this story out into the world at a time when Iranian women urgently need people to remember they exist, and are full human beings, too. Zan, zendegi, azadi. Women, life, freedom.Fact: Looking Back At Genre History by Amy H. SturgisSupport this show http://supporter.acast.com/starshipsofa. Hosted on Acast. See acast.com/privacy for more information.

Isa thinks citrus fruits do not evoke boobs. Isabel Yap writes stories about girls and monsters. By day she builds product with devs and designers. Born and raised in Manila, she has lived and worked in the US since 2010. Her debut story collection, Never Have I Ever, was published in 2021 by Small Beer Press and has been a finalist for the Locus, Crawford, Ignyte, World Fantasy, and British Fantasy Awards. She is @visyap on Twitter and her website is https://isabelyap.com. Subscribe to our Patreon and get access to patrons-only perks at  patreon.com/underthebleacherspod! Find out more at https://under-the-bleachers.pinecast.co

We sat down with Ukrainian author RB Lemberg to talk about their book The Four Profound Weaves, which was a Nebula, Ignyte, and Locus award finalist. It is a story of two mature (for a wonderful change) transgendered people going off on an heroic journey to discover who they are and what they can do in the Birdverse world. … Continue...Episode 148 – Interview with RB Lemberg

Dr Milhem discusses the unique mechanism of action and delivery method of RP1, which is being evaluated in the IGNYTE trial for patients with solid tumors, as well as the parallel studies ARTACUS and CERPASS, which are further exploring the agent.

This week Joe is joined by Air Force Veteran Max Aulakh, the founder and CEO of Ignyte Assurance Platform. Max served in Security Forces, deploying to both Iraq and Afghanistan. He transitioned out of the military in 2009, during a difficult job market, and started working as a defense contractor. Max entered the world of cybersecurity and entrepreneurship. He discusses the importance of market validation, his journey for the American dream, and details about his latest company Ignyte Assurance Platform.  Check out more about Ignyte Assurance Platform here.  About Our Guest  Max Aulakh is the CEO and Founder of Ignyte Assurance Platform. He is recognized for his expertise in automating all aspects of DoD & Commercial cyber compliance issues. He gained his start in security as a U.S Air Force Security Leader during Operation Iraqi Freedom and Operation Enduring Freedom, where he built his first-of-kind cyber readiness inspection automation capability to identify and analyze vulnerabilities and threats to mission-critical systems supporting the military. He went out and started several cybersecurity products and formed different companies including his latest venture Ignyte Assurance. He is a business leader but also a technical practitioner. Max is routinely sought after for his advice and input into meeting complex cyber federal standards. He has presented at major security conferences. Join the conversation on Facebook! Check out Veteran on the Move on Facebook to connect with our guests and other listeners. A place where you can network with other like-minded veterans who are transitioning to entrepreneurship and get updates on people, programs and resources to help you in YOUR transition to entrepreneurship. About Our Sponsors Navy Federal Credit Union  Navy Federal Credit Union helps you take control of your finances after the holidays. You can get a low intro APR on their Platinum Credit Card, it's their lowest rate card and it's a great tool to pay down debt. Navy Federal even has multiple savings and investing options to help you get closer to your financial goals. They offer digital tools and educational resources to help guide your decisions. With Navy Federal, you can automate your savings and investing to put your money to work for you, even as you sleep. Plus, you can buy fractional shares. Learn more at navyfederal.org. Savings products insured by NCUA. Investment options are available through Navy Federal Investment Services and are not insured by NCUA. At Navy Federal, our members are the mission.     Camp Lejeune Historic Drinking Water  If you or a loved one were stationed at Camp Lejeune prior to 1985, please visit here to register for the notification database, to find more information on benefits, and project updates.    Want to be our next guest? Send us an email at interview@veteranonthemove.com.  Did you love this episode? Leave us a 5-star rating and review!  Download Joe Crane's Top 7 Paths to Freedom or get it on your mobile device. Text VETERAN to 38470. Veteran On the Move podcast has published over 410 episodes. Our listeners have the opportunity to hear in-depth interviews conducted by host Joe Crane. The podcast features people, programs, and resources to assist veterans in their transition to entrepreneurship.  As a result, Veteran On the Move has over 7,000,000 verified downloads through Stitcher Radio, SoundCloud, iTunes and RSS Feed Syndication making it one of the most popular Military Entrepreneur Shows on the Internet Today

My final discussion of the novels by Jessie Redmon Fauset is with Tonia Ransom from The Nightlight Podcast. We dig deep into Fauset's novel “Comedy:  American Style”. This novel explores the desires of a family matriarch's commitment to passing for white and the effect it has on her children. Faucet presents the dynamics of passing from several different perspectives. Tonia's deep and personal views on the story are a delight to hear. We also delve into how Fauset presents the world of the Black middle and upper class of Philadelphia in the 1920s. Our conversation also explores the way Jessie depicts the lives of women during this period of history.   Tonia Ransom is the creator of the Nightlight podcast. The podcast is dedicated to showcasing horror fiction by Black authors. You will hear new and classic horror fiction by Black authors professionally read. If you have an interest in horror and always wanted to find stories in the genre that center Black people, this podcast is perfect for you. Tonia also features interviews with many of the authors of the works presented. In 2021, the podcast earned the IGNYTE award for Best Fiction Podcast. When Tonia is not producing an award-winning podcast, she is busy writing her own horror fiction. You can explore the Nightlight podcast here. NIGHTLIGHT – A Black Horror Podcast (nightlightpod.com) Also, you can listen to a previous interview I conducted with Tonia here.

Go Follow Ignyte on YouTube, Instagram Support his music Career --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/hoodcelebrity/support

Bethany C. Morrow and CB Lee join the cast to talk about how to approach writing historical fiction, problems that crop up when writers don't do proper research for the time period and society they are trying to represent and the peoples and cultures that are often left out of the narrative. Bethany C. Morrow is  an Indie Bestselling author who writes for adult and young adult audiences, in genres ranging from speculative literary to contemporary fantasy to historical. She is author of the novels MEM and A SONG BELOW WATER, which is an Audie, Ignyte and Locus finalist. She is editor/contributor to the young adult anthology TAKE THE MIC, the 2020 ILA Social Justice in Literature award winner. Her work has been chosen as Indies Introduce and Indie Next picks, and featured in The LA Times, Forbes, Bustle, Buzzfeed, and more. She is included on USA TODAY's list of 100 Black novelists and fiction writers you should read. You can find more about her and buy her books here. CB Lee is a Lambda Literary Award nominated writer of young adult and middle grade fiction. Her works include the Juinor Library Guild selected A Clash of Steel: A Treasure Island Remix (Feiwel and Friends), the Sidekick Squad series (Duet Books), Ben 10 graphic novels (Boom! Studios), Out Now: Queer We Go Again (HarperTeen), Minecraft: The Shipwreck (Del Rey Books), From A Certain Point Of View: The Empire Strikes Back (Del Rey Books). Lee's work has been featured in Teen Vogue, Wired Magazine, Hypable, Tor's Best of Fantasy and Sci Fi and the American Library Association's Rainbow List. For more about her and to buy her books, visit her website. If you'd like to read the chapter we critiqued with our notes, you can find it here. To find out how to support Lit Service, get extra content (like the video versions of these episodes, bonus hot seat critiques and occasional other bonus material, as well as opportunities to get critiques from the cast) visit our Patreon!

We have finalists in the Ignyte awards, Locus awards, some upcoming release dates for new Green Bone Saga stories and why Robb Dunewood has stopped worrying and learned to love the Murderbot.

Hosted by Austin T. Gullett, this trailer will be a sneak peak into Ignyte Your Why Podcast. IYWP is a platform to help amplify the voices of authentic people to have unfiltered conversations about their why & to also discuss current events & the impact it has on their lives. IYW was created too inspire and to Ignyte Their Why. SEASON 1 OFFICIALLY DROPS ON THURSDAY JANUARY 7TH, 2021 Social Media: IG: @ignyteyourwhy Twitter: @ignyteyourwhy Facebook: Ignyte Your Why

Well, that surely was an episode. We do our best to reflect on the season as a whole and consider why some of these decisions might've been made. We try to identify a few of the things that we felt were missing to have made it work. And how do we feel about where the characters are now? It depends. We've still got some transcripts to finish, but will be on hiatus otherwise for the foreseeable future. Ruth: If you're missing Lovecraft Country, we encourage you to check out the IGNYTE awards finalists list for tons of new worlds to explore. The awards are sponsored by FIYAHCon, for BIPOC+ in speculative fiction, to “celebrate the vibrancy and diversity of the current and future landscapes of science fiction, fantasy, and horror." The awards include novels, novellas, short stories, young adult, comics, anthologies, podcasts and more. It includes some of my favorite reading of the last year, plus plenty of stuff for my to-read and listen lists! Intro music from "The Ninth Crewman" by Patrick de Arteaga. Outro music "In the Pines" performed by Micah Tillman.

Sharifah and Jenn discuss the Ignyte and World Fantasy Awards, women in SF history, and give you some starting points to dive into fanfiction. This episode is sponsored by TBR: Tailored Book Recommendations, Vault Comics and #1 New York Times Bestselling author Brandon Sanderson’s new, original hardcover graphic novel DARK ONE, and Black Sun by Rebecca Roanhorse. Subscribe to the podcast via RSS here, Apple Podcasts here, Spotify here. The show can also be found on Stitcher here. To get even more SF/F news and recs, sign up for our Swords and Spaceships newsletter! News: “Every Possible Kind of Science Fiction Story” 2020 World Fantasy Award Finalists Ray Bradbury Readathon 2020 Inaugural Ignyte Awards Nominees Links & References “Homestead” by katemonkey (Finn/Poe/Rey after events of Rise of Skywalkers) Authors who have written fanfic The Rec Center email newsletter Archive of Our Own / AO3 FanFiction.net (FFN) The most popular tags on AO3 Fanfic subreddit (resources for readers and writers) Recs on Reddit Wattpad The Promise and Potential of Fan Fiction, on The New Yorker See omnystudio.com/policies/listener for privacy information.

It is not often that you find yourself in a situation where your state government calls you for help. That is what happened to Kendra Karczewski, Enterprise Technology Advisor at Stratosphere Networks.  While activating their internal team, who is she going to call? Her trusted advisor and team Avant lead by President Drew Lydecker. This is an amazing story with loads of insight on how private industry comes together to respond to the needs of their state and beloved city. McCormick Place is a massive convention center that was designated as an emergency hospital location that will house 3000 patient beds. Kendra’s task was to coordinate the major task of getting the communications for the hospital set up. Drew Lydecker Kendra Karczewski Once Drew was contacted, Avant jumped into action and started assembling a team of companies that would be involved.  That team included: Stratosphere Networks – A multifaceted IT managed service provider Evolve IP - a provider of collaboration, workspaces and contact centers for healthcare organizations Ignyte - a provider of collaboration, workspaces and contact centers for healthcare organizations RapidScale - Is a global managed cloud services provider Spectrotel – A national next-generation aggregator Synoptek - A leading provider of HIPAA-compliant healthcare information technology Trustwave - A leading cybersecurity and managed security services Listen in to both Drew and Kendra describe the total team effort that was successfully completed to help stem the overflow of the hospital systems due to the CoronaVirus outbreak. While the process was brutally hard with long hours and loaded with stress, the goal of saving lives in Chicago during worldwide emergency was accomplished! For more information, go to: https://www.stratospherenetworks.com/ or https://goavant.net/

Live Audio From IGNYTE w/Blaqrose Supreme - 11/17/18 Listen, Like, Repost, Share & Enjoy. Facebook : www.facebook.com/everyoneknowsrose/ Instragram : instagram.com/everyoneknowsrose Website : everyoneknowsrose.com/ Subscribe To My Podcast Soundcloud : bit.ly/2J1wVAm iTunes : apple.co/2IYVjCA Google Play : bit.ly/2IZPO6T Spotify : spoti.fi/2J4migo

Live Audio From IGNYTE w/Blaqrose Supreme - 11/17/18 Listen, Like, Repost, Share & Enjoy. Facebook : www.facebook.com/everyoneknowsrose/ Instragram : instagram.com/everyoneknowsrose Website : everyoneknowsrose.com/ Subscribe To My Podcast Soundcloud : bit.ly/2J1wVAm iTunes : apple.co/2IYVjCA Google Play : bit.ly/2IZPO6T Spotify : spoti.fi/2J4migo

Live Audio From IGNYTE w/Blaqrose Supreme - 11/17/18 Listen, Like, Repost, Share & Enjoy. Facebook : www.facebook.com/everyoneknowsrose/ Instragram : instagram.com/everyoneknowsrose Website : everyoneknowsrose.com/ Subscribe To My Podcast Soundcloud : bit.ly/2J1wVAm iTunes : apple.co/2IYVjCA Google Play : bit.ly/2IZPO6T Spotify : spoti.fi/2J4migo

Taking Risks with Brian Lischer of Ignyte Brands Brian Lischer, Founder, and CEO of Ignyte, is an entrepreneur, author, speaker, and brand strategist. He is a leading voice on a range of issues, including the psychology of branding. Brian founded Ignyte, an award-winning branding agency, in 2013. After working for more than a decade in […] The post MFL 57 – Taking Risks with Brian Lischer of Ignyte Brands appeared first on MIND FOR LIFE.

What's Up, Creative Hustlers! Today Steven, from Impact Hub Siracusa Sicily, is talking with Brian Lisher, CEO and Chief Brand Strategist with Ignyte, a badass branding firm out of San Diego, CA. [01:04] What's up Brian, ready to get hustling? [01:19] Why Brian is a Creative Hustler, and more about Ignyte. [02:25] How Brian manages converging sociology and psychology into Ignyte. [04:37] Brian wanted to fix the brand, instead of promoting the brand. [05:40] Even Alan has a psychology degree. The greatest marketers are psychologists. [07:00] Started with a social media consulting contract, and moved into branding. [08:00] Ignyte has been open for 4 years, but really 3 full years. [9:30] How Steven defines brand. [11:00] How Brian defines brand. [11:35] How Brian brings data into shaping perceptions. [13:15] It's important to know how a CEO views you vs. a Marketing Manager. [15:15] Why there isn't always a direct ROI. [16:40] Sometimes you have to adjust pricing to meet the competition. [17:00] It's more expensive and harder to be a change agent. [18:45] If it comes down to arguing about price, it is probably the wrong client. [20:26] Sometimes your competitors are 10x the price, but not 10x the value. [21:46] Where does inspiration come from? [23:14] Without having partners or high level staff, much of the work falls on Brian. [24:40] How Brian deals with late night resurgence in creativity. [25:24] Being able to do the analysis and turning it into data for creative execution is what Brian loves. [26:40] What Brian is excited about for 2018: Growth, public speaking and more. [29:30] Brian's secret to balancing the building of a business is working with an HR consultant, and developing a hiring process. [30:48] Process is everything. [31:32] Brian's choice for grabbing a drink with a Creative Hustler: Steve Jobs. [33:35] People not be able to tell detail and obsession that went into a project, but they can feel it. [36:07] Brian is a minimalist, and needs to work with others like him. [38:19] There's two types of people who do pitches. 10 slides & no words, or 300 slides and tons of words. [39:15] Where Brian & Ignyte live on the internet. [40:55] As always, check out The Creative Hustler, or Latin & Code, and please leave a review. [41:13] Melissa's Moment of Hustle. Contact: Twitter.com/BrianLischer IgnyteBrands.com

I interviewed Brian Lischer, the CEO of Ignyte Branding Agency, about the neuroscience of marketing and the degree to which basic colors and shapes inform many of the fundamental decisions we make. He also educated me on crazy topics like The Sequence of Cognition, Triune Brain Theory, and Panopticism.  With over a decade of experience in branding, digital marketing, and design, Brian has worked with brands in the industries of healthcare, life sciences, technology, financial services, and more. His work has been featured in major publications including Forbes, Entrepreneur, Huffington Post, and Brand Quarterly. Inc. Magazine named him one of the top branding experts in the country.

[Live] LIVE episode from SoCal Marketing Club: How to Scale Your E-Commerce Business Like a Badass With John Bertino, Alan Bush, Steven Picanza, and Melissa Rautenberg! We're having a blast!   [00:30] What's up Creative Hustlers! [01:00] Biggie isn't overrated… [01:13] Live at the Loading Dock in Little Italy, in SoCal. [01:30] This is John's first event on his own! [02:35] Got to chat with Josh Fechter! [02:40] You need to join Josh's Facebook group! [03:30] Here's the Interview with Josh Fechter! [04:00] So what is Growth Hacking and BAMF Media? [05:00] BAMF Media was built to handle clients. [05:21] What clients for BAMF Media look like… [06:10] Josh growth hacked his way to Mark Zuckerberg. [06:50] Facebook's Developer Conference in Chicago! [07:20] Facebook is actually running a Facebook Test Group for admins of Big Facebook Groups! [07:58] What's in store for Live SoCal Marketing event! [08:05] Some of the interviews of the night: Caden from CPC Strategy,and Nathan from Sourcify. [08:50] Where you can find Josh on the internet! [09:30] Look for Josh on a future episode, hopefully! [10:15] Steven was serious about if Josh could take down Zuckerberg. [10:54] The next interview we had was Brian Lischer! [11:17] Brian is great at Business to Business branding. [11:50] It's almost like Barbalicious! [12:15] Brian is really cerebral, and very into psychology, mythology and culture. [12:27] Brian is a really unique interview from the crowd at the event. [12:50] It's all about the internal brand! [13:05] It's the interview with Brian Lischer! [13:30] Brian works at Ignyte, and Alan works with Ignite Visibility. [14:08] What Brian does, and why Ignyte is different! [14:50] It's getting to the essence of the brand, and rebuilding around that. [15:26] Branding is expensive but a LOT goes into it. [16:03] It's going to cost more to do a REBRAND wrong! [16:33] Why Ignyte is different from others. [16:55] The external brand is only ONE SIDE of the coin! [17:40] For some companies, it's about experience in store, and when calling support! [18:49] Educating people on TRUE branding. [19:05] What BRANDING is NOT! [19:20] The craziest thing about branding… [19:59] Branding is just chemicals in the brain. [20:25] Brian just did a workshop in New York figuring out their Brand Archetype. [20:57] Where you can find Brian and Ignyte on the internet! [21:33] Tons of value at the SoCal Marketing event. [22:12] Well done to John Bertino for the event! [22:40] Some of the great speakers on the panel. [23:27] Moderating a panel is hard work. [24:40] Open mixer with SoCal Marketing Club for Entrepreneurs in San Diego.Stay Tuned for details! [25:50] Where John and the So Cal Marketing Club live on the internet! [26:28] John Bertino is always on the show. [26:57] Peace Out, Creative Hustlers [27:02] Melissa's Moment of Hustle Contact Info for Interviewees:   Josh Fechter Co-Founder BAMF Media     Website: http://www.bamf.media/ Private FB group: https://www.facebook.com/groups/growthmarketers LinkedIn profile: https://www.linkedin.com/in/joshuafechter   Brian Lischer - CEO Ignyte Brands   Website: http://www.ignytebrands.com/ LinkedIn: https://www.linkedin.com/in/lischer/ Facebook: https://www.facebook.com/ignytebrands/   John Bertino Website: Theagencyguy.com Twitter: @theagencyguyinc Linked In: John Bertino Email: john@theagencyguy.com SoCalMarketing Club: @SCMarketingClub / www.socalmarketingclub.com

Brian Lischer is a branding, digital marketing, and design expert. He is the founder and CEO of Ignyte, a branding agency that specializes in brand strategy, identity, and storytelling. His work has been published in major publications, such as Forbes, Huffington Post, and Brand Quarterly. He was listed as #1 Branding Expert to Look for in 2017 by Inc! Free 30 day Audible Trial- http://www.audibletrial.com/WhatGotYouThere Sunniva Super Coffee- Use discount code WGYT for 20% off your order!- www.drinksupercoffee.com DSTLD-Just go to DSTLD.com right now and use the promo code JOURNEY10 (in all caps) at checkout to get 10% off your first purchase. http://www.brianlischer.com/ http://www.ignytebrands.com/ LinkedIn- https://www.linkedin.com/in/lischer/ Twitter- https://twitter.com/BrianLischer Twitter- https://twitter.com/ignytebrands Sean DeLaney Instagram- https://www.instagram.com/seandelaney23/ Facebook- https://www.facebook.com/whatgotyouthere/ Twitter- https://twitter.com/SeanDeLaney23 Intro/Outro music by Justin Great- http://justingreat.com/ Audio Engineer- Brian Lapres   

Brands are a lot like people. The companies and organizations we own or work for all have values, beliefs, and aspirations that they attempt to live up to every day. Sometimes however, our brands begin to drift away from those stated values and the resulting gap is perceived by our clients and customers as an inauthentic brand. Brain Lischer is the founder of Ignyte, a branding agency whose sole focus is on helping drifting brands achieve alignment and authenticity. With a background in psychology, and a deep curiosity in understanding how and why people make decisions and perceive brands in certain ways, Brian and his team dive into the process of helping clients rebrand with academic level research and strategy. After coming to the realization years ago that he himself was living an inauthentic life, Brian has dedicated his life to understanding authenticity through the lens of branding and perception, and is here today to share his insights with us. Many of the benefits of branding are hard to measure, but they are also much farther reaching than we might think. Whether or not you’re happy with where your brand is at right now, Brian will help you evaluate it in an objective manner and determine if your brand - and you - are living authentically.

"We’re an eclectic group of creative professionals obsessed with brand experience." - Brian Lischer Brian Lischer - Founder and CEO of Ignyte Brian Lischer, Founder and CEO of Ignyte, is an entrepreneur, author, speaker, and brand strategist. He is a leading voice on a range of issues, including the psychology of branding. Brian founded Ignyte, an award-winning branding agency, in 2013. After working for more than a decade in marketing and design, he decided to put his passion for behavioral sciences to work by helping brands discover and express their authenticity. Under Brian’s leadership, Ignyte has grown into a highly sought-after agency that transforms brands around the globe. Brian works closely with the agency’s key accounts to ensure optimal positioning and authentic brand experiences. Brian studied psychology and communication at the University of California San Diego. A frequent blogger, speaker, and columnist, Brian has written for publications including Forbes, Huffington Post, and Brand Quarterly. Major media outlets cite him as a branding expert and successful entrepreneur. Brian is an active member of the Young Entrepreneurs Council, Entrepreneurs' Organization, MIT Enterprise Forum, and American Marketing Association. He is an advisor to startups and is also involved as an investor and partner in a range of digital ventures. Brian donates his time and resources to charitable organizations helping to create positive change in the world. In addition to his various business ventures, Brian is a devoted thrill-seeker and can often be found surfing, snowboarding or mountaineering. When he’s not in the mountains or the sea, Brian dedicates his time to developing his mindfulness practice, which includes yoga, meditation and Buddhist teachings. Connect with Brian: Website | Personal Website | Twitter | LinkedIn Subscribe to the Outlier Newsletter: Click Here Brought to you by: If you enjoy Outlier On Air, please Subscribe & Review on iTunes or Stitcher